Reviewer's report

Title: Economic analyses to support decisions about HPV vaccination in low and middle income countries: a guide for analysts

Version: 1 Date: 27 November 2012

Reviewer: Evan Myers

Reviewer's report:

A clearly written, thoughtful summary of a consensus conference by the leading investigators in this area which should prove useful for investigators, reviewers, and editors--hopefully, all future papers in this area will cite this one and follow its recommendations. I have no substantive changes to suggest.

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have received research funding in the past for economic analyses of HPV vaccination in the US from Merck, Inc, and currently serve as a consultant to Merck regarding next-generation HPV vaccines.

I currently receive research funding from GSK, Inc, another manufacturer of HPV vaccines, for an observational study of reproductive outcomes after treatment for preinvasive cervical disease.

I have been a co-author with Dr. Kim in the past, most recently as members of the panel developing cervical cancer screening guidelines for the American Cancer Society (previous co-authorship was more than 5 years previously)

I do not believe any of these potential competing interests influenced my review of this paper, which draws no conclusions about the relative effectiveness or cost-effectiveness of HPV vaccination (and thus has has no direct benefit to either Merck or GSK), and I believe that my working relationship with Dr. Kim has not precluded an objective evaluation of the paper.